Login / Signup

Selective delipidation of Mycobacterium bovis BCG retains antitumor efficacy against non-muscle invasive bladder cancer.

Niannian JiMeijun LongAndreu Garcia-VilanovaRussell AultJuan I MolivaKizil A YusoofNeelam MukherjeeTyler J CurielHong DixonJordi B TorrellesRobert S Svatek
Published in: Cancer immunology, immunotherapy : CII (2022)
These data support clinical investigation of dBCG-Tokyo as a treatment for patients with BCG-intolerant NMIBC.
Keyphrases
  • muscle invasive bladder cancer
  • mycobacterium tuberculosis
  • electronic health record
  • big data
  • machine learning
  • combination therapy
  • artificial intelligence
  • deep learning